James Stein of the University of Wisconsin-Madison said that the result was only barely statistically significant, and could be due to the fact that patients on ARBs lived longer and were more likely to get diagnosed with cancer. Moreover, there is no known biological reason these drugs would increase cancer risk.
Office of Strategic Communication